Amarin (AMRN) vs Capricor Therapeutics (CAPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Amarin (AMRN) over the past year, gaining 32.0% versus a loss of 35.5%. Over five years, CAPR leads with a +122.6% price change compared with -85.5% for AMRN. Amarin is the larger company by market cap ($444.4 million vs $441.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | CAPR |
|---|---|---|
| Share price | $10.57 | $7.59 |
| Market cap | $444.39M | $441.30M |
| 1-day change | -6.13% | +0.80% |
| YTD return | -24.28% | -73.70% |
| 1-year return | -35.47% | +32.00% |
| 5-year return | -85.48% | +122.58% |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | $0 |
| Revenue growth (YoY) | -6.55% | -100.00% |
| Net income (latest FY) | $-38.80M | $-105.04M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | — |
| Net margin | -18.16% | — |
| 52-week high | $17.31 | $40.37 |
| 52-week low | $10.56 | $2.96 |
| Distance from 52-week high | -38.94% | -81.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +22.99% | +259.03% |
| Average volume | 79.50K | 4.73M |
| Shares outstanding | 42.04M | 58.14M |
| Employees | 80 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed AMRN by 67.5 percentage points over the past year.
- Amarin grew revenue faster in its latest fiscal year (-6.55% vs -100.00%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
AMRN vs CAPR FAQ
Which is bigger, Amarin or Capricor Therapeutics?
Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $441.30M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, AMRN or CAPR?
CAPR returned +32.00% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Capricor Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.